Adverse prognostic value of peritumoral vascular invasion: Is it abrogated by adequate endocrine adjuvant therapy? Results from two international breast cancer study group randomized trials of chemoendocrine adjuvant therapy for early breast cancer

Annals of Oncology

Volumn 21, Issue 2, 2010, Pages 245-254

  Viale, G ^a   Giobbie Hurder, A ^b   Gusterson, B A ^c   Maiorano, E ^d   Mastropasqua, M G ^a   Sonzogni, A ^a   Mallon, E ^c   Colleoni, M ^e   Castiglione Gertsch, M ^f   Regan, M M ^b   Price, K N ^g   Brown, R W ^h   Golouh, R ⁱ   Crivellari, D ^j   Karlsson, P ^k   Hlschlegel, C O ^l   Gelber, R D ^m   Goldhirsch, A ^e,n   Coates, A S ^o,p  

^a UNIVERSITY OF MILAN   (Italy)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d UNIVERSITY OF BARI   (Italy)

^e EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^f International Breast Cancer Study Group Coordinating Center   (Switzerland)

^g International Breast Cancer Study Group Statistical Center   (United States)

^h MELBOURNE PATHOLOGY   (Australia)

ⁱ INSTITUTE OF ONCOLOGY   (Slovenia)

^j CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^k SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^l SWISS GROUP FOR CLINICAL CANCER RESEARCH SAKK   (Switzerland)

^m FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

ⁿ ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^o International Breast Cancer Study Group   (Switzerland)

^p UNIVERSITY OF SYDNEY   (Australia)

more..

Author keywords

Adjuvant therapy; Breast cancer; Endocrine responsiveness; Metastasis; Prognosis; Vascular invasion

Indexed keywords

CYCLOPHOSPHAMIDE; FLUOROURACIL; GOSERELIN; HORMONE RECEPTOR; METHOTREXATE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; CMF REGIMEN;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER INVASION; CANCER PROGNOSIS; CANCER RECURRENCE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DISTANT METASTASIS; DRUG EFFICACY; EARLY CANCER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REGIONAL METASTASIS; TREATMENT OUTCOME; TUMOR VOLUME; ADJUVANT CHEMOTHERAPY; AGED; BREAST TUMOR; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE COURSE; MENOPAUSE; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PHYSIOLOGY; PREDICTION AND FORECASTING; PROGNOSIS; VASCULARIZATION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DISEASE PROGRESSION; FEMALE; FLUOROURACIL; GOSERELIN; HUMANS; MENOPAUSE; METHOTREXATE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TREATMENT OUTCOME;

EID: 77951926837     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp317     Document Type: Article

References (32)

1. Davis BW, Gelber R, Goldhirsch A et al. Prognostic significance of peritumoral vessel invasion in clinical trials of adjuvant therapy for breast cancer with axillary lymph node metastasis. Hum Pathol 1985; 16: 1212-1218.
2. Colleoni M, Rotmensz N, Maisonneuve P et al. Prognostic role of the extent of peritumoral vascular invasion in operable breast cancer. Ann Oncol 2007; 18: 1632-1640.
3. Neville AM, Bettelheim R, Gelber RD et al. Factors predicting treatment responsiveness and prognosis in node-negative breast cancer. The International (Ludwig) Breast Cancer Study Group. J Clin Oncol 1992; 10: 696-705.
4. Lauria R, Perrone F, Carlomagno C et al. The prognostic value of lymphatic and blood vessel invasion in operable breast cancer. Cancer 1995; 76: 1772-1778.
5. Weigand RA, Isenberg WM, Russo J et al. Blood vessel invasion and axillary lymph node involvement as prognostic indicators for human breast cancer. Cancer 1982; 50: 962-969.
6. Pinder SE, Ellis IO, Galea M et al. Pathological prognostic factors in breast cancer. III. Vascular invasion: relationship with recurrence and survival in a large study with long-term follow-up. Histopathology 1994; 24: 41-47.
7. Straume O, Akslen LA. Independent prognostic importance of vascular invasion in nodular melanomas. Cancer 1996; 78: 1211-1219.
8. Lee AH, Pinder SE, Macmillan RD et al. Prognostic value of lymphovascular invasion in women with lymph node negative invasive breast carcinoma. Eur J Cancer 2006; 42: 357-362.
9. Mirza AN, Mirza NQ, Vlastos G et al. Prognostic factors in node-negative breast cancer: a review of studies with sample size more than 200 and follow-up more than 5 years. Ann Surg 2002; 235: 10-26.
10. Krasna MJ, Flancbaum L, Cody RP et al. Vascular and neural invasion in colorectal carcinoma. Incidence and prognostic significance. Cancer 1988; 61: 1018-1023.
11. Inada K, Shimokawa K, Ikeda T et al. The clinical significance of venous invasion in cancer of the stomach. Jpn J Surg 1990; 20: 545-552.
12. Leissner J, Koeppen C, Wolf HK. Prognostic significance of vascular and perineural invasion in urothelial bladder cancer treated with radical cystectomy. J Urol 2003; 169: 955-960.
13. Shields TW. Prognostic significance of parenchymal lymphatic vessel and blood vessel invasion in carcinoma of the lung. Surg Gynecol Obstet 1983; 157: 185-190.
14. International Breast Cancer Study Group. Prognostic importance of occult axillary lymph node micrometastases from breast cancers. Lancet 1990; 335: 1565-1568.
15. Viale G, Zurrida S, Maiorano E et al. Predicting the status of axillary sentinel lymph nodes in 4351 patients with invasive breast carcinoma treated in a single institution. Cancer 2005; 103: 492-500.
16. International Breast Cancer Study Group. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial. JNCI Cancer Spectr 2003; 95: 1833-1846.
17. International Breast Cancer Study Group. Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial. J Natl Cancer Inst 2002; 94: 1054-1065.
18. Viale G, Regan MM, Maiorano E et al. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors- International Breast Cancer Study Group. J Clin Oncol 2008; 26: 1404-1410.
19. Aebi S, Gelber S, Castiglione-Gertsch M et al. Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? Lancet 2000; 355: 1869-1874.
20. Early Breast Cancer Trialists' Collaborative Group. Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials. Lancet 2008; 371: 29-40.
21. Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958; 53: 457-481.
22. Cox DR. Regression models and life tables (with discussion). J R Stat Soc 1972; B34: 187-220.
23. Gray RJ. A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 16: 1141-1154.
24. Lee AK, DeLellis RA, Silverman ML et al. Lymphatic and blood vessel invasion in breast carcinoma: a useful prognostic indicator? Hum Pathol 1986; 17: 984-987.
25. Gilchrist KW, Gould VE, Hirschl S et al. Interobserver variation in the identification of breast carcinoma in intramammary lymphatics. Hum Pathol 1982; 13: 170-172.
26. Bettelheim R, Mitchell D, Gusterson BA. Immunocytochemistry in the identification of vascular invasion in breast cancer. J Clin Pathol 1984; 37: 364-366.
27. Martin SA, Perez-Reyes N, Mendelsohn G. Angioinvasion in breast carcinoma. An immunohistochemical study of factor VIII-related antigen. Cancer 1987; 59: 1918-1922.
28. Kato T, Kameoka S, Kimura T et al. The combination of angiogenesis and blood vessel invasion as a prognostic indicator in primary breast cancer. Br J Cancer 2003; 88: 1900-1908.
29. Obermair A, Czerwenka K, Kurz C et al. Tumor vascular invasion in breast cancer. Hematoxylin-eosin versus immunohistochemistry staining for factor VIII antigen. Dtsch Med Wochenschr 1994; 119: 1491-1496.
30. Saigo PE, Rosen PP. The applicability of immunohistochemical stains to identify endothelial-lined channels in mammary carcinoma. Cancer 1987; 59: 51-54.
31. van den Eynden GG, van der Auwera I, van Laere SJ et al. Distinguishing blood and lymph vessel invasion in breast cancer: a prospective immunohistochemical study. Br J Cancer 2006; 94: 1643-1649.
32. Mohammed RAA, Martin SG, Gill MS et al. Improved methods of detection of lymphovascular invasion demonstrate that it is the predominant method of vascular invasion in breast cancer and has important clinical consequences. Am J Surg Pathol 2007; 31: 1825-1833.